Myopia is a highly frequent ocular disorder worldwide and pathologic myopia is the 4th most
common cause of irreversible blindness in developed countries. Pathologic myopia is …

Complications from pathologic myopia are a major cause of visual impairment and
blindness, especially in east Asia. The eyes with pathologic myopia may develop loss of the …

Purpose To develop a classification and grading system for myopic maculopathy. Design
Development and evaluation of a classification system for myopic maculopathy based on …

Objective To compare the efficacy and safety of ranibizumab 0.5 mg, guided by visual acuity
(VA) stabilization or disease activity criteria, versus verteporfin photodynamic therapy (vPDT) …

Purpose To evaluate intravitreal aflibercept 2 mg in patients with myopic choroidal
neovascularization (CNV). Design An international, phase III, multicenter, randomized …

Pathologic myopia is a leading cause of visual impairment. Development of myopic
choroidal neovascularization (CNV) is one of the most common complications that leads to …

Background Intravitreal anti–vascular endothelial growth factor (VEGF) therapy is now
considered the gold standard for the treatment of various retinal disorders. As therapy has …

Topic The aim of this article is to review and compile available information on the
classification, pathophysiology, and clinical features of myopic choroidal neovascularization …

Choroidal neovascularisation (CNV) is a common vision-threatening complication of myopia
and pathological myopia. Despite significant advances in understanding the epidemiology …

Purpose: To evaluate the efficacy and safety of ranibizumab 0.5 mg in adult patients with
choroidal neovascularization because of an uncommon cause enrolled in the 12-month …